Header Logo

Connection

Ian Sanne to Antiretroviral Therapy, Highly Active

This is a "connection" page, showing publications Ian Sanne has written about Antiretroviral Therapy, Highly Active.
  1. Incident pregnancy and time to death or AIDS among HIV-positive women receiving antiretroviral therapy. PLoS One. 2013; 8(3):e58117.
    View in: PubMed
    Score: 0,345
  2. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. J Int AIDS Soc. 2012 Mar 12; 15(1):13.
    View in: PubMed
    Score: 0,323
  3. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):500-6.
    View in: PubMed
    Score: 0,282
  4. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15.
    View in: PubMed
    Score: 0,263
  5. Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. AIDS. 2020 04 01; 34(5):681-686.
    View in: PubMed
    Score: 0,141
  6. Citizenship status and engagement in HIV care: an observational cohort study to assess the association between reporting a national ID number and retention in public-sector HIV care in Johannesburg, South Africa. BMJ Open. 2017 01 24; 7(1):e013908.
    View in: PubMed
    Score: 0,113
  7. Vitamin D, D-dimer, Interferon ?, and sCD14 Levels are Independently Associated with Immune Reconstitution Inflammatory Syndrome: A Prospective, International Study. EBioMedicine. 2016 Feb; 4:115-23.
    View in: PubMed
    Score: 0,105
  8. Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol. 2016 07; 100(1):223-31.
    View in: PubMed
    Score: 0,104
  9. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health. 2014 May; 19(5):490-8.
    View in: PubMed
    Score: 0,092
  10. Effect of antiretroviral therapy on patients' economic well being: five-year follow-up. AIDS. 2014 Jan 28; 28(3):417-24.
    View in: PubMed
    Score: 0,092
  11. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013 Nov 19; 16:18794.
    View in: PubMed
    Score: 0,091
  12. Tenofovir use and pregnancy among women initiating HAART. AIDS. 2012 Nov 28; 26(18):2393-7.
    View in: PubMed
    Score: 0,085
  13. Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr. 2012 Aug 15; 60 Suppl 3:S96-104.
    View in: PubMed
    Score: 0,083
  14. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis. 2012 Sep; 55(6):868-76.
    View in: PubMed
    Score: 0,082
  15. Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification. PLoS Med. 2012; 9(4):e1001207.
    View in: PubMed
    Score: 0,081
  16. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011 Sep 17; 11:244.
    View in: PubMed
    Score: 0,078
  17. Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS One. 2011; 6(8):e22778.
    View in: PubMed
    Score: 0,077
  18. Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study. J Int AIDS Soc. 2011 Jul 29; 14:37.
    View in: PubMed
    Score: 0,077
  19. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol. 2011 Oct; 17(5):438-47.
    View in: PubMed
    Score: 0,077
  20. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):349-55.
    View in: PubMed
    Score: 0,076
  21. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan 01; 52(1):128-37.
    View in: PubMed
    Score: 0,074
  22. Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010 Oct; 10(7):937-46.
    View in: PubMed
    Score: 0,073
  23. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):480-4.
    View in: PubMed
    Score: 0,070
  24. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010 Mar 27; 24(6):915-9.
    View in: PubMed
    Score: 0,070
  25. Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa. Acta Cytol. 2009 Jan-Feb; 53(1):10-7.
    View in: PubMed
    Score: 0,065
  26. CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S131-40.
    View in: PubMed
    Score: 0,060
  27. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr. 2007 Sep 01; 46(1):91-100.
    View in: PubMed
    Score: 0,059
  28. Deciding when to institute terminal palliative care for AIDS patients--an evidence-based approach. S Afr Med J. 2001 Jul; 91(7):559-60.
    View in: PubMed
    Score: 0,038
  29. Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. AIDS. 2019 11 01; 33(13):2049-2059.
    View in: PubMed
    Score: 0,034
  30. Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: A model of uptake and adherence to care. PLoS One. 2018; 13(8):e0201955.
    View in: PubMed
    Score: 0,032
  31. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10.
    View in: PubMed
    Score: 0,031
  32. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.
    View in: PubMed
    Score: 0,027
  33. Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014 Jun; 23:56-62.
    View in: PubMed
    Score: 0,023
  34. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013 Nov 15; 208(10):1624-8.
    View in: PubMed
    Score: 0,022
  35. HIV-associated lipodystrophy in South Africa: the impact on the patient and the impact on the plastic surgeon. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):839-44.
    View in: PubMed
    Score: 0,022
  36. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
    View in: PubMed
    Score: 0,021
  37. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,020
  38. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
    View in: PubMed
    Score: 0,020
  39. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
    View in: PubMed
    Score: 0,018
  40. Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010 Jun; 15 Suppl 1:43-7.
    View in: PubMed
    Score: 0,018
  41. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009 Jun 01; 48(11):1617-23.
    View in: PubMed
    Score: 0,017
  42. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008 Jul 23; 300(4):423-30.
    View in: PubMed
    Score: 0,016
  43. Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS. 2008 Jul; 22 Suppl 1:S131-9.
    View in: PubMed
    Score: 0,016
  44. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 05; 17(18):2603-14.
    View in: PubMed
    Score: 0,011
  45. T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment. AIDS. 2003 May 23; 17(8):1145-9.
    View in: PubMed
    Score: 0,011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.